Skip to main content
. 2021 May 6;80(10):1312–1316. doi: 10.1136/annrheumdis-2021-220461

Table 2.

Empirical and estimated marginal means by study groups and treatment

Group Empirical mean (SD) EMM* (95% CI)
Controls 9.36 (1.85) 8.48 (8.12 to 8.85)
IMIDs all 6.47 (3.14) 6.90 (6.45 to 7.35)
IMIDs b/tsDMARDs 6.49 (2.91) 6.90 (6.22 to 7.58)
csDMARDs 6.26 (3.00) 6.67 (5.84 to 7.50)
Untreated 6.64 (3.70) 7.13 (6.30 to 7.96)

*Adjusted for age, sex, time elapsed from first vaccination date to sampling date.

bDMARDs, biological disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; EMM, estimated marginal mean; IMIDs, immune-mediated inflammatory diseases; tsDMARDs, targeted-synthetic disease-modifying antirheumatic drugs.